Patients

Treating Cancer with Precision


Cancer is a Disease of the Genome

Of the 20,000 genes that make up the human genome, about 400 genes are known to be highly associated with cancer. If mutations occur in genes that control important functions such as cell growth, it can cause cells to multiply out of control, leading to tumor formation.

With cancer genomic testing, now we can quickly decode the tumor DNA and identify cancer-related mutations. Knowing the mutations that drive the patient's cancer empowers the physicians to tailor treatment options for each patient.

genetic mutation
cancer formation
cancer formation



Finding the Right Treatment for You

Patients with the same type of cancer often carry different genetic mutations, so two lung cancer patients may need different treatments because their tumors have different genetic mutations. Comprehensive genomic profiling allows physicians to identify the optimal treatment for each patient. This patient-specific approach is called “precision medicine.”

Standard Approach to Cancer
Cancer Precision Medicine



More Options, with Better Precision

Genomic profiling can sometimes find more treatment options for patients. Because patients of different cancer types may carry the same cancer-causing mutations, a drug approved for breast cancer, for example, may benefit a lung cancer patient who has a genetic alteration more commonly seen in breast cancer. 

Targeted cancer treatment



Cancer management is highly complex. In addition to genomic profiles, the physician needs to consider many factors including the patient's conditions and treatment history. It is therefore essential to discuss with your doctor and have your doctor comprehensively evaluate whether genomic testing is right for you. You can also contact us to learn more.

Contact Us



Cancer Treatment

How does genomic testing make cancer treatment more effective?

Genomic testing can identify the mutations that drive the patient's tumor growth. Since patients of the same cancer type often carry different mutations, genomic testing allows doctors to select the optimal treatments based on the individual's genomic profile. On the other hand, patients with different cancer types may harbor the same genetic mutations, so genomic profiling can sometimes identify more treatment options across cancer types. For example, a drug approved for breast cancer may benefit a lung cancer patient carrying a genetic alteration more commonly seen in breast cancer.

Is immunotherapy right for me?

Immunotherapy has shown impressive and durable results on some patients. However, the biggest challenge immunotherapy faces is its low response rate, with only about 20% of patients responding to treatment. It is therefore critical to identify patients who are likely to benefit in advance. ACTOnco+ comprehensive genomic profiling can predict response to immunotherapy, helping doctors evaluate whether immunotherapy is right for you.

 

Comprehensive Genomic Profiling

  • For all solid tumors

  • Evaluates targeted, immune, hormone and chemo therapy

  • Predicts immunotherapy responses

  • Screens 440 cancer-related genes


Targeted Genomic Profiling

  • For lung, breast, colorectal and gastric cancer

  • Evaluates targeted therapy

  • Screens 40 druggable genes

BRCA1/2 Testing

  • For breast, ovarian, pancreatic and prostate cancer

  • Evaluates targeted therapy

  • Screens BRCA1/2 genes


Cancer Monitoring

How do I monitor my cancer?

Cancer needs to be monitored during and after treatment to detect residual cancer after surgery, monitor if the tumor is shrinking, and check for drug resistance or cancer recurrence. Traditional ways to monitor cancer include detecting tumor proteins levels, such as the CEA or CA-125 tests, and conducting imaging examinations such as CT scans. A new way to monitor cancer is to detect tumor DNA circulating in the blood, called ctDNA (Circulating tumor DNA).

Through a simple blood test, ACTMonitor™ genomic testing analyzes the tumor DNA to look for genetic mutations correlated with drug resistance, assess if treatments are working, and detect cancer recurrence earlier than traditional methods.



Cancer Monitoring

  • Real-time monitoring through blood specimen

  • Detects drug resistance

  • Assesses treatment responses

 


Cancer Prevention

Have I inherited genetic mutations related to cancer?

Approximately 5-10% of cancers are hereditary, and the most common hereditary cancers are breast, colorectal, ovarian, prostate, pancreatic and kidney cancer. Hereditary cancers are caused by mutations in cancer-related genes, such  as BRCA1/2. Understanding the hereditary cancer risk enables high-risk individuals to start taking actions for cancer prevention and early detection.

ACTRisk™ is a genetic test that helps physicians and genetic counselors to precisely evaluate cancer risk and discuss risk management options with high-risk individuals.


Hereditary Risk Evaluation

  • Analyzes 32 genes

  • Evaluates risk for common hereditary cancers

 

Patient Stories

Mr. Yu, Taiwan

Mr. Yu, Taiwan

Stage 4 Lung Cancer Survivor

“Cancer completely changed my perspective on life. Now I focus on enjoying life and trying to make the most out of every day. I’m glad my doctor told me about comprehensive genomic profiling that found more treatment options for me.”

Andrew Tay, MD

A liver cancer survivor in Singapore

“To date I have done three rounds of Genomic Profiling Analysis semi-annually to monitor my liver tumor genes mutation activities. In case I have a recurrence, or develop a secondary cancer, I will stand a better chance to treat it at early stage.”

How to Get Tested

Service Overview

1 Turnaround time is counted after the received sample passes ACT Genomics sample quality control test
2 Formalin-fixed and paraffin-embedded (FFPE)
3 Peripheral blood mononuclear cell (PBMC)

 

Q&A

Understanding Precision Medicine

Genes are DNA sequences that carry hereditary information. This information defines the traits of a cell and is necessary to maintain normal cell functions. Humans have approximately 20,000 genes.
A gene mutation is a permanent change in the sequence of chemical bases in a cell’s DNA. Mutations occur frequently in the human body. Some mutations are not harmful, but other mutations may cause the proteins encoded by the gene to function incorrectly or not at all. This, in turn, prevents the cell from working properly and can cause diseases such as cancer.
Among the 20,000 human genes, about 300-400 are related to cancer. If a mutation occurs in one of those genes, this may cause an uncontrolled growth of the affected cell by a dysregulation of the cell growth signaling pathway in which the mutated gene plays a role. Since patients have their own individual mutation patterns affecting different genes and pathways, targeted therapy only works for patients in which the targeted pathways are altered.
Precision medicine analyzes mutations in cancer-related genes to find out what drives your cancer, enabling the identification of targeted therapies that directly interfere with tumor growth. Because gene mutations are different for individual patients, you are more likely to benefit from therapies that are tailored for your cancer.
The mutations in cancer-related genes are identified by an analysis of tumor samples using a high-throughput method called next-generation sequencing (NGS). This method allows a rapid and comprehensive gene analysis. Through bioinformatics data processing and utilizing clinical databases, gene mutations are matched with the appropriate targeted therapies to provide patients and doctors with personalized treatment options.